Modulight: Start of the year was still difficult
In connection with its business review, Modulight released key business indicators on Friday. The company's Q1’23 revenue and EBIT fell from the comparison period and were clearly below our expectations. Despite the undershoot, our estimates fall only slightly, as the company reported that several projects had significant revenue potential during the rest of the year. The valuation picture is practically unchanged when the share price has fallen as much as our estimates.
Modulight
Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.
Read more on company pageKey Estimate Figures01.05.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 4.6 | 9.1 | 12.6 |
growth-% | -49.30 % | 98.73 % | 37.55 % |
EBIT (adj.) | -7.8 | -5.2 | -2.9 |
EBIT-% (adj.) | -169.49 % | -56.72 % | -22.75 % |
EPS (adj.) | -0.20 | -0.12 | -0.06 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |